HealthTechCrunch Editors

Hospitals evaluate health IT through six parallel gatekeepers, not one champion.

Hit rate, not price tag, determines which screening method actually saves money.

The FDA's seven-step framework sets the first clear rules for trustworthy AI in drug approvals.

Digital twins update continuously with new data.

Algorithms now systematize the serendipitous drug discoveries that once relied on pure luck.

A guide to which platforms match your molecule type and discovery stage.

AlphaFold's predicted structures unlock drug targets that were invisible to chemistry before.

Explaining which part of drug discovery computational methods actually touch, not just invoking AI.

AI tools could catch melanomas earlier in primary care, where most patients start.

Early AI alerts catch sepsis hours before clinicians can, but real-world results lag the hype.

Regulators require clinical trials to prove AI diagnostics work in real clinical settings.

Models trained on skewed datasets underdiagnose patients from underrepresented groups at scale.

AI dominates narrow, pattern-heavy tasks but loses ground fast when cases get messy or ambiguous.

Radiology dominates FDA-cleared AI approvals, but clearance means safety review, not clinical proof.

Hospitals need a framework for evaluating AI tools that evolve after purchase.

Doctors must explain how AI contributed to a diagnosis, not just the result itself.

Broadband gaps and device access combine to block rural telehealth adoption.

Video therapy works about as well as in-person sessions for most mental health conditions.

Pandemic flexibilities for prescribing controlled substances remain in legal limbo five years later.

Five telehealth models compete on recurring revenue, regulatory risk, and patient retention.

Real clinical work determines which telehealth model actually works.

Congress finally made behavioral health telehealth permanent while other services expire in 2027.

Establish governance and multidisciplinary teams before evaluating platforms, not after.

Behavioral health telehealth thrives where other specialties struggle.

Regulatory approval separates legitimate pain treatment from wellness apps making empty claims.

Wearables now capture continuous disease signals labs can only measure in snapshots.

Statutory gaps and broken billing codes leave prescribed software uncoverable.

Independent testing reveals accuracy gaps manufacturers don't always disclose.

How software gets classified as a medical device shapes which FDA review pathway it must follow.

Clinical evidence and reimbursement clarity matter more than FDA clearance alone.

Default analytics tools on healthcare websites violate federal law without proper safeguards.

Four agencies share jurisdiction, and their rules constantly overlap.

Standard analytics can't track the patient journeys that actually drive healthcare conversions.

Patients now decide on providers digitally before they ever call.

Consumers want wellness products but distrust health claims.

Split your marketing message between families and referral partners.

Compliance risk and tight budgets demand strategic frameworks before channels and campaigns.

Declining referral fulfillment rates mean agencies must build intake systems, not just chase growth.